Themis Medicare

Which are the latest news on Themis Medicare?

Why is Themis Medicare Ltd falling/rising?

As of 05-Sep, Themis Medicare Ltd's stock price is at 120.60, down 3.17% after recent gains, and has underperformed its sector. The stock showed volatility during intraday trading, with decreased investor participation and a significant drop in delivery volume.

As of 05-Sep, Themis Medicare Ltd's stock price is falling, currently at 120.60, which reflects a decrease of 3.95 or 3.17%. This decline comes after a brief period of gains, as the stock has fallen following two consecutive days of increases. Additionally, the stock underperformed its sector by 1.6% today. <BR><BR>Intraday trading showed volatility, with the stock reaching a high of Rs 127.65, but it also dipped to a low of Rs 119.9. The weighted average price indicates that more volume was traded closer to this lower price, suggesting a lack of strong buying interest. Furthermore, there has been a notable decrease in investor participation, with delivery volume dropping by 51.96% compared to the 5-day average. <BR><BR>Despite some positive performance over longer periods, such as a 19.82% increase year-to-date, the current trend and day’s performance indicate a downward movement in the stock price.

Who are in the management team of Themis Medicare?

Themis Medicare's management team includes key individuals such as Sachin D Patel (Managing Director and CEO), Dinesh S Patel (Chairman), and several independent directors like Vijay Gopi Kishan Agarwal and Hari Subramaniam, ensuring a mix of executive leadership and independent oversight.

Themis Medicare has a diverse management team that includes several key individuals:<BR><BR>1. **Rajneesh Anand** - Non-Executive & Non-Independent Director<BR>2. **Vijay Gopi Kishan Agarwal** - Independent Non-Executive Director<BR>3. **Hari Subramaniam** - Independent Non-Executive Director<BR>4. **Reena S Patel** - Non-Executive Director<BR>5. **Sachin D Patel** - Executive Director, Managing Director, CEO, and Promoter<BR>6. **Dinesh S Patel** - Chairman & Independent Director<BR>7. **Manjul Sandhu** - Independent Non-Executive Director<BR>8. **Bhaskar Vemban Iyer** - Independent Non-Executive Director<BR>9. **Shishir Dalal** - Additional Director<BR>10. **Reena S Patel** - Alternate Director<BR><BR>This team brings a mix of executive and independent oversight to the company, contributing to its governance and strategic direction.

What does Themis Medicare do?

Themis Medicare Ltd, a Micro Cap company in the Pharmaceuticals & Biotechnology sector, reported net sales of 87 Cr and a net profit of 25 Cr for June 2026. Founded in 1969, it focuses on pharmaceutical products and has a market cap of INR 1,156 Cr.

Overview: <BR>Themis Medicare Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History: <BR>Themis Medicare Limited was incorporated in 1969 as 'Themis Chemicals Limited'. The company underwent a name change in 2001 and reported its most recent quarterly results for June 2026, with net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Net Sales: 87 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 25 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 1,156 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.40% <BR>Debt-Equity: 0.23 <BR>Return on Equity: 0.50% <BR>Price to Book: 2.91<BR><BR>Contact Details: <BR>Address: Plot No 69 A GIDC Indl Estate, Vapi Valsad Gujarat : 396195 <BR>Tel: 91-260-2421675 <BR>Email: themis@themismedicare.com <BR>Website: http://www.themismedicare.com

Who are the peers of the Themis Medicare?

Themis Medicare's peers include Amrutanjan Health, Fermenta Biotec, Sigachi Industries, Lincoln Pharma, Bajaj Healthcare, Kopran, Bharat Parenter, Wanbury, Remus Pharma, and Accent Microcell. In terms of management risk, growth, and capital structure, Amrutanjan Health and Kopran show excellent management risk, while Themis Medicare has below-average growth and capital structure.

Peers: Themis Medicare's peers include Amrutanjan Healt, Fermenta Biotec., Sigachi Indust., Lincoln Pharma., Bajaj Healthcare, Kopran, Bharat Parenter., Wanbury, Remus Pharma, and Accent Microcell.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amrutanjan Healt and Kopran, while Average management risk is found at Fermenta Biotec., Sigachi Indust., Lincoln Pharma., Bajaj Healthcare, Wanbury, and Remus Pharma, and the rest. Below Average management risk is noted for Bharat Parenter. Growth is Below Average for Amrutanjan Healt, Fermenta Biotec., Sigachi Indust., Lincoln Pharma., Themis Medicare, Bajaj Healthcare, Kopran, Bharat Parenter., Wanbury, and the rest, while Remus Pharma shows Good growth. Capital Structure is Excellent for Amrutanjan Healt, Sigachi Indust., and Lincoln Pharma, Good for Kopran, and Below Average for Themis Medicare, Bajaj Healthcare, Bharat Parenter., Wanbury, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Fermenta Biotec. at 57.50%, while the lowest is Amrutanjan Healt at -26.26%. Themis Medicare's 1-year return of 26.14% is higher than Amrutanjan Healt's but lower than Fermenta Biotec's. Additionally, Wanbury is the only peer with a negative six-month return.

How big is Themis Medicare?

As of 31st August, Themis Medicare Ltd has a market capitalization of 1,156.00 Cr, classifying it as a Micro Cap company, with recent net sales of 331.61 Cr and a net profit of 39.97 Cr.

As of 31st August, Themis Medicare Ltd has a market capitalization of 1,156.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest four quarters, Themis Medicare reported Net Sales of 331.61 Cr and a Net Profit of 39.97 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 402.60 Cr and Total Assets of 588.03 Cr.

Should I buy, sell or hold Themis Medicare Ltd?

Are Themis Medicare Ltd latest results good or bad?

Themis Medicare Ltd's latest results show a return to profitability with a net profit of ₹8.89 crores for Q4 FY26, but significant concerns arise from a 15.09% decline in net sales and compressed operating margins, indicating potential operational challenges. Investors should be cautious due to reliance on non-operating income for profitability.

Themis Medicare Ltd's latest results present a mixed picture. On one hand, the company has returned to profitability, reporting a consolidated net profit of ₹8.89 crores for Q4 FY26, compared to a loss in the same quarter last year. This represents a positive turnaround year-on-year.<BR><BR>However, when looking at the quarter-on-quarter performance, there are significant concerns. The net sales decreased by 15.09% from the previous quarter, and operating margins have sharply compressed from 10.86% to 4.91%. This decline in revenue and margin raises questions about the company's operational stability and sustainability.<BR><BR>Additionally, the profit after tax (PAT) margin did see a slight improvement, but it was largely supported by non-operating income, which accounted for a substantial portion of the profit before tax. This heavy reliance on non-operating income could be a red flag for investors regarding the sustainability of the reported profitability.<BR><BR>Overall, while the return to profit is a positive sign, the significant revenue decline and margin compression indicate that Themis Medicare is facing operational challenges that could impact its future performance. Investors should approach the company's prospects with caution until there is clearer evidence of consistent operational improvement.

When is the next results date for Themis Medicare Ltd?

The next results date for Themis Medicare Ltd is 28 May 2026.

The next results date for Themis Medicare Ltd is scheduled for 28 May 2026.

Is Themis Medicare technically bullish or bearish?

As of November 25, 2025, the technical trend has shifted to a bearish stance, supported by daily moving averages and weekly Bollinger Bands, despite some short-term bullish signals from the KST.

As of 25 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include the daily moving averages showing bearish momentum and the weekly Bollinger Bands confirming a bearish trend. The MACD on a monthly basis is also bearish, while the weekly KST is mildly bullish, indicating some divergence in shorter time frames. Overall, the bearish sentiment is reinforced by the significant negative returns over the past month and year, contrasting sharply with the broader market performance.

How has been the historical performance of Themis Medicare?

Themis Medicare has shown growth in net sales and total assets from March 2019 to March 2025, increasing from INR 183.75 crore to INR 405.51 crore in sales. However, profitability has declined, with profit after tax dropping from INR 61.54 crore in March 2022 to INR 23.90 crore in March 2025.

Answer:<BR>The historical performance of Themis Medicare shows a fluctuating trend in key financial metrics over the years, with notable changes in revenue, profit, and expenses.<BR><BR>Breakdown:<BR>Themis Medicare's net sales have generally increased from INR 183.75 crore in March 2019 to INR 405.51 crore in March 2025, despite a dip in March 2022. Total operating income followed a similar pattern, reaching INR 405.51 crore in March 2025. However, total expenditure has also risen, amounting to INR 356.46 crore in March 2025, which includes significant costs such as raw materials and employee expenses. Operating profit, excluding other income, has fluctuated, peaking at INR 95.63 crore in March 2022 before declining to INR 49.05 crore in March 2025. Profit before tax showed a decline from INR 83.92 crore in March 2022 to INR 33.74 crore in March 2025, while profit after tax also decreased from INR 61.54 crore to INR 23.90 crore in the same period. The company's total assets grew from INR 345.34 crore in March 2020 to INR 588.03 crore in March 2025, with total liabilities increasing from INR 345.34 crore to INR 588.03 crore as well. Cash flow from operating activities improved to INR 34 crore in March 2025, although the net cash outflow was recorded at INR 3 crore. Overall, Themis Medicare has experienced growth in sales and assets, but profitability has faced challenges in recent years.

Is Themis Medicare overvalued or undervalued?

As of August 4, 2025, Themis Medicare's valuation has shifted from attractive to risky due to significant overvaluation indicated by a negative PE ratio of -103.96 and poor stock performance, with a year-to-date return of -60.97%, contrasting unfavorably with peers like Sun Pharma and Cipla.

As of 4 August 2025, Themis Medicare's valuation grade has moved from attractive to risky, indicating a significant deterioration in its market position. The company is currently overvalued based on its financial ratios, which include a PE ratio of -103.96, an EV to EBITDA of 103.48, and a Price to Book Value of 2.34. These figures suggest that the company's earnings are not only negative but also that it is trading at a substantial premium relative to its book value.<BR><BR>In comparison to its peers, Themis Medicare's valuation stands out unfavorably; for instance, Sun Pharma has a PE ratio of 34.25 and an EV to EBITDA of 23.19, while Cipla shows a more attractive PE of 22.7 and an EV to EBITDA of 15.96. The stark contrast in these ratios highlights Themis Medicare's overvaluation in the current market. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -60.97%, significantly underperforming the Sensex, which has gained 3.69% in the same period.

Who are the top shareholders of the Themis Medicare?

The top shareholders of Themis Medicare include Vividhmargi Investments Pvt Ltd at 15.78%, individual investors with a collective 24.14%, and Anuj Anantrai Sheth as the highest public shareholder at 4.58%. Additionally, 13 foreign institutional investors hold a small portion of 0.1%, while mutual funds have no significant holdings.

The top shareholders of Themis Medicare include a mix of promoters and individual investors. The majority of the shares are held by promoters, with Vividhmargi Investments Pvt Ltd being the largest shareholder at 15.78%. Individual investors collectively hold 24.14% of the shares, while the highest public shareholder is Anuj Anantrai Sheth, who owns 4.58%. Additionally, there are 13 foreign institutional investors (FIIs) holding a small portion of 0.1%, and mutual funds have not reported any significant holdings.

Has Themis Medicare declared dividend?

Themis Medicare Ltd has declared a 50% dividend, amounting to ₹0.5 per share, with an ex-date of July 12, 2024. While recent total returns show volatility with negative performance over the last 6 months and 1 year, longer-term returns have been more favorable.

Themis Medicare Ltd has declared a 50% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 50%<BR>- Amount per share: 0.5<BR>- Ex-date: Jul-12-2024<BR><BR>Dividend Yield: 0.36%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -53.28%, with a dividend return of 0%, resulting in a total return of -53.28%.<BR><BR>Over the past year, the price return was -35.38%, the dividend return was 0.23%, leading to a total return of -35.15%.<BR><BR>In the 2-year period, the price return was -7.2%, the dividend return was 3.84%, culminating in a total return of -3.36%.<BR><BR>For the 3-year period, the price return was 73.83%, with a dividend return of 14.40%, resulting in a total return of 88.23%.<BR><BR>In the last 4 years, the price return was 76.12%, the dividend return was 20.90%, which gives a total return of 97.02%.<BR><BR>Over the past 5 years, the price return was 299.5%, with a dividend return of 47.83%, leading to an impressive total return of 347.33%.<BR><BR>Overall, Themis Medicare has declared a dividend, but the recent total returns indicate significant volatility, particularly in the short term, with negative returns over the last 6 months and 1 year, while longer-term returns show a more favorable performance.